{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/atrial-fibrillation/prescribing-information/beta-blockers-except-sotalol/","result":{"pageContext":{"chapter":{"id":"a2c20504-f7cb-54cc-adc0-c0cb70ec0ccb","slug":"beta-blockers-except-sotalol","fullItemName":"Beta-blockers (except sotalol)","depth":2,"htmlHeader":"<!-- begin field 3b425b86-0dca-40f3-8b84-b8288ae0ca62 --><h2>Beta-blockers (except sotalol)</h2><!-- end field 3b425b86-0dca-40f3-8b84-b8288ae0ca62 -->","summary":"","htmlStringContent":"<!-- begin item 2169a5fc-d42e-40cb-b7e7-d50913b8e4b7 --><!-- end item 2169a5fc-d42e-40cb-b7e7-d50913b8e4b7 -->","topic":{"id":"c61747eb-a307-5da3-9878-9e952f2e1246","topicId":"e42fc175-7ae7-44c7-b7ef-b58a14733e7e","topicName":"Atrial fibrillation","slug":"atrial-fibrillation","lastRevised":"Last revised in October 2020","chapters":[{"id":"15747365-1cc2-550f-ad60-639db7df4ff0","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"9ced6fef-0141-5375-b1c4-37d2756e7678","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"75cb268e-28e7-51c1-87dd-0a86fbc0616b","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"1390db2e-6367-52cb-9af5-792d2e4d9310","slug":"changes","fullItemName":"Changes"},{"id":"f65a3e88-8f57-5c09-867a-ba88262e838c","slug":"update","fullItemName":"Update"}]},{"id":"16591b01-3ee5-5b14-a7e2-7a5226294933","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"f3967a51-562c-5a5b-b55a-02dd39bfcbe9","slug":"goals","fullItemName":"Goals"},{"id":"5a66a5f8-9497-5664-abc1-d16cfe63bdd4","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"0ca3b265-f279-56a1-94f0-c0e96dbeaaff","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"8bf96582-45d8-507c-9772-4c1092b4bd6a","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"992b55c8-2134-5283-b0f7-34608af53bd1","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"677bafba-be09-57b3-a169-096ee3aa3fa1","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"b6e491b1-6724-5c59-b127-fc29812ea52f","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"dab901c7-1cc0-5253-a4e0-e5b5bc04ba5e","slug":"definition","fullItemName":"Definition"},{"id":"39c5efdc-48cc-5b0a-85d7-f7da2de67a25","slug":"causes","fullItemName":"Causes"},{"id":"211e1811-bd20-5cfb-b7b9-c06c3fd223a3","slug":"prevalence","fullItemName":"Prevalence"},{"id":"96a3b3f8-183a-52b6-9909-a81f0fd999dd","slug":"complications-prognosis","fullItemName":"Complications and prognosis"}]},{"id":"fc0c1acd-3cda-53a5-85ae-be117589c6bb","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"0a1e6d67-1c9c-5ea9-a30c-006e32e641c7","slug":"diagnosis-of-atrial-fibrillation","fullItemName":"Diagnosis of atrial fibrillation"}]},{"id":"42efe54e-8ff7-5283-ad5f-7dabdd2dcdff","fullItemName":"Management","slug":"management","subChapters":[{"id":"a955511a-8fbf-5bf9-aa82-b0e634a6325b","slug":"management-of-af","fullItemName":"Scenario: Management of AF"}]},{"id":"c2a59ca9-6ff7-533b-912e-d7ba0cc5fcb9","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"a2c20504-f7cb-54cc-adc0-c0cb70ec0ccb","slug":"beta-blockers-except-sotalol","fullItemName":"Beta-blockers (except sotalol)"},{"id":"d02a47f9-0498-503c-9cb1-0c3f89766d4f","slug":"diltiazem-verapamil","fullItemName":"Diltiazem and verapamil"},{"id":"037e75e8-454f-5dcd-a0b8-3e9ff5a5b309","slug":"digoxin","fullItemName":"Digoxin"},{"id":"c0c53c1d-4cd9-5e70-8a01-3d5f59d213cb","slug":"anticoagulants","fullItemName":"Anticoagulants"},{"id":"49e47ec1-0743-51db-a133-a2eed45d0eb0","slug":"aspirin-clopidogrel","fullItemName":"Aspirin and clopidogrel"},{"id":"5cb461d2-9502-5698-a467-30edd459c1b3","slug":"amiodarone-not-initiated-in-primary-care","fullItemName":"Amiodarone - not initiated in primary care"},{"id":"0fae1520-f160-57a2-af90-5b46bb20bdf5","slug":"sotalol-not-initiated-in-primary-care","fullItemName":"Sotalol - not initiated in primary care"}]},{"id":"1048ec97-41b1-5f93-a54d-1f58a8a56528","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"5fff0dc2-1e01-590e-a159-76736c6a2ac0","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"b4497d2f-172b-54a5-99c6-5cd92c8469ba","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"d1d9c4e5-758a-5a99-93e3-4d2099a68d60","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"0b86c2fd-54d8-569a-a8a8-ccadd53c17a0","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"e7ea1b2f-6198-53f7-b4f8-681296a03562","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"3a114d83-bf8b-5507-b946-6af4f46c529e","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"5bbaf83e-cca2-55f4-a4c9-e6b808387a89","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"c2a59ca9-6ff7-533b-912e-d7ba0cc5fcb9","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"b3915a8a-7cb2-5ef7-8f7a-a39196b46295","slug":"choice-of-beta-blocker","fullItemName":"Choice of beta-blocker","depth":3,"htmlHeader":"<!-- begin field 9dd1a26c-a9f1-4eab-ba5b-9df937323de4 --><h3>Which beta-blocker should I use?</h3><!-- end field 9dd1a26c-a9f1-4eab-ba5b-9df937323de4 -->","summary":"","htmlStringContent":"<!-- begin item 67d76edc-6635-471a-9980-b70d5ca4c55f --><!-- begin field 3f95bdec-6861-41c1-8689-dffadc0fde88 --><ul><li>Atenolol, acebutolol, metoprolol, nadolol, oxprenolol, and propranolol are licensed to treat atrial fibrillation (AF).</li><li>The National Institute for Health and Care Excellence (NICE) does not specify which beta-blocker should be used to treat AF. The choice of beta-blocker will usually depend on the person's comorbidities, local policy, and cost. The following recommendations are based on pragmatic advice:<ul><li><strong>For people with AF alone, </strong>atenolol may be preferred because it may be taken once a day and is less expensive than other beta-blockers.<ul><li>The usual dose is 50–100 mg a day.</li><li>Check pulse and blood pressure 1 week after each dose titration to assess response to treatment. See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/atrial-fibrillation/management/management-of-af/#follow-up\">follow-up</a> for more information.</li></ul></li><li><strong>For people who have AF and have had a previous myocardial infarction (without heart failure), </strong>metoprolol (standard release), propranolol (standard release), or atenolol may be preferred. For further information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/mi-secondary-prevention/\">MI - secondary prevention</a>.</li><li><strong>For people with AF and heart failure, </strong>bisoprolol, carvedilol, or nebivolol may be preferred. For further information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/heart-failure-chronic/\">Heart failure - chronic</a>.</li><li><strong>For people with AF and diabetes mellitus, </strong>a cardioselective beta-blocker (such as atenolol, bisoprolol, metoprolol, nebivolol, and acebutolol [to a lesser extent]) is preferred. Avoid beta-blockers in people who experience frequent hypoglycaemia.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/atrial-fibrillation/references/\">NICE, 2014b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/atrial-fibrillation/references/\">Joint Formulary Committee, 2019</a>]</p><!-- end field 3f95bdec-6861-41c1-8689-dffadc0fde88 --><!-- end item 67d76edc-6635-471a-9980-b70d5ca4c55f -->","subChapters":[]},{"id":"bbbee38b-f888-5657-868e-469c328c3ce6","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field df942325-5357-4de0-8f54-06ddb2d5fcb9 --><h3>What are the contraindications and cautions of beta-blockers?</h3><!-- end field df942325-5357-4de0-8f54-06ddb2d5fcb9 -->","summary":"","htmlStringContent":"<!-- begin item b349db2a-4687-491d-87c5-42f08a21a519 --><!-- begin field b59109a3-49fc-48c5-ae3a-412242bb1812 --><ul><li><strong>Do not prescribe beta-blockers to people with:</strong><ul><li>A history of obstructive airways disease (such as asthma and chronic obstructive pulmonary disease) or bronchospasm. However, if there is no alternative, a cardioselective beta-blocker (such as bisoprolol and atenolol) can be used under specialist supervision.<ul><li>Treatment should be initiated at the lowest possible dose and the person should be monitored for new symptoms (such as dyspnea or exercise intolerance). Concomitant bronchodilator therapy is recommended.</li></ul></li><li>Cardiogenic shock or phaeochromocytoma (without a concomitant alpha-blocker).</li><li>Second- or third-degree heart block (in the absence of a permanent pacemaker).</li><li>Sick sinus syndrome.</li><li>Sinus bradycardia (heart rate less than 60 beats per minute at the start of treatment).</li><li>Severe hypotension (systolic less than 100 mmHg).</li><li>Severe peripheral arterial disease (pain at rest and sometimes intermittent claudication) — the blood pressure-lowering properties of beta-blockers can exacerbate symptoms.</li><li>Uncontrolled heart failure.<ul><li>Seek specialist advice before starting a beta-blocker in people with a current or recent exacerbation of heart failure.</li></ul></li></ul></li><li><strong>Beta-blockers should be used with caution in people with:</strong><ul><li>Diabetes.</li><li>First-degree atrioventricular (AV) block.</li><li>Myasthaenia gravis.</li><li>Portal hypertension — due to risk of deteriorating liver function.</li><li>Psoriasis.<ul><li>Note: Be aware that use of a beta-blocker can mask symptoms of hypoglycaemia and thyrotoxicosis.</li></ul></li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/atrial-fibrillation/references/\">ABPI, 2019a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/atrial-fibrillation/references/\">ABPI, 2018a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/atrial-fibrillation/references/\">ABPI, 2019b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/atrial-fibrillation/references/\">ABPI, 2018b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/atrial-fibrillation/references/\">ABPI, 2017a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/atrial-fibrillation/references/\">ABPI, 2019c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/atrial-fibrillation/references/\">Joint Formulary Committee, 2019</a>]</p><!-- end field b59109a3-49fc-48c5-ae3a-412242bb1812 --><!-- end item b349db2a-4687-491d-87c5-42f08a21a519 -->","subChapters":[]},{"id":"26b62d6a-3c3b-53ad-b668-0fa0c94e0c21","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 5f1a7e1d-8f12-4d93-9515-1dabfa3e6067 --><h3>What are the adverse effects of beta-blockers?</h3><!-- end field 5f1a7e1d-8f12-4d93-9515-1dabfa3e6067 -->","summary":"","htmlStringContent":"<!-- begin item 077212cc-ea23-4582-8949-a777eb21fa3c --><!-- begin field 191c4cce-8026-46b1-8d31-4ba1fba6e8e8 --><p><strong>Adverse effects of beta-blockers include:</strong></p><ul><li>Bradycardia.</li><li>Bronchospasm.</li><li>Cold extremities, paraesthesiae, and numbness — these are more common in people with peripheral vascular disease. If troublesome, beta-blockers might need to be stopped.</li><li>Conduction disorders.</li><li>Dizziness.</li><li>Dyspnoea.</li><li>Exacerbation of psoriasis.</li><li>Exacerbation of Raynaud's phenomenon.</li><li>Fatigue — an incidence of approximately 18 per 1,000 people treated with a beta-blocker has been reported.</li><li>Gastrointestinal disturbances.</li><li>Headache.</li><li>Heart failure.</li><li>Hyperglycaemia/hypoglycaemia — in people with or without diabetes.</li><li>Hypotension.</li><li>Impotence and loss of libido — occurs in approximately five people per 1,000 receiving treatment.</li><li>Paraesthesia.</li><li>Peripheral vasoconstriction.</li><li>Psychoses.</li><li>Purpura.</li><li>Sleep disturbance or nightmares — this occurs less frequently with water-soluble beta-blockers, such as atenolol, because these drugs are less likely to cross the blood-brain barrier.</li><li>Thrombocytopenia.</li><li>Vertigo.</li><li>Visual disturbances.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/atrial-fibrillation/references/\">ABPI, 2019a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/atrial-fibrillation/references/\">ABPI, 2018a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/atrial-fibrillation/references/\">ABPI, 2019b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/atrial-fibrillation/references/\">ABPI, 2018b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/atrial-fibrillation/references/\">ABPI, 2017a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/atrial-fibrillation/references/\">ABPI, 2019c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/atrial-fibrillation/references/\">Joint Formulary Committee, 2019</a>]</p><!-- end field 191c4cce-8026-46b1-8d31-4ba1fba6e8e8 --><!-- end item 077212cc-ea23-4582-8949-a777eb21fa3c -->","subChapters":[]},{"id":"95f10769-d928-5d94-a7cc-932fbc93041a","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field a90de0ee-9e4b-4713-9c78-3cde7a386bbf --><h3>What key drug interactions of beta-blockers should I be aware of?</h3><!-- end field a90de0ee-9e4b-4713-9c78-3cde7a386bbf -->","summary":"","htmlStringContent":"<!-- begin item bd404169-ecd4-473b-b3fe-bb3b442dda29 --><!-- begin field 619d8181-ab39-44ed-82ed-6a8e35797d42 --><p><strong>Drug interactions with beta-blockers include:</strong></p><ul><li><strong>Alpha-blockers, alprostadil, ACE-inhibitors, angiotensin II receptor antagonists, anxiolytics, baclofen, co-beneldopa, co-careldopa, diazoxide, diuretics. hydralazine, hypnotics, levodopa, MAOIs, methyldopa, minoxidil, moxonidine, nitrates, phenothiazines, sodium nitroprusside, tizanidine </strong>— enhanced hypotensive effect.</li><li><strong>Antidepressants</strong><ul><li>Tricyclics, mirtazapine, and trazodone should be prescribed with caution in people taking beta-blockers, as there is an increased risk of postural hypotension.</li></ul></li><li><strong>Antidiabetics</strong> — beta-blockers may mask warning signs of hypoglycaemia, such as tremor.</li><li><strong>Calcium channel blockers</strong><ul><li>The combination of a beta-blocker and verapamil should not be prescribed because bradycardia, asystole, severe hypotension, and heart failure can occur.</li><li>Caution should be used if prescribing diltiazem with a beta-blocker — monitor pulse and blood pressure carefully, as bradycardia and atrioventricular block can occur. Asystole and sudden death have also been reported.</li><li>The combination of a beta-blocker and nifedipine can cause severe hypotension and heart failure.</li><li>The combination of a beta-blocker and other calcium channel blockers can lead to enhanced antihypertensive effect.</li></ul></li><li><strong>Class I </strong><strong>anti-arrhythmics</strong><strong> (such as quinidine, flecainide)</strong><ul><li>The combination of a beta-blocker and a class I anti-arrhythmic is not recommended because bradycardia and myocardial depression can occur.</li></ul></li><li><strong>Class III </strong><strong>anti-arrhythmics</strong><strong> (such as amiodarone)</strong><ul><li>The combination of a beta-blocker and amiodarone should be prescribed with caution as there is an increased risk of bradycardia, atrioventricular (AV) block, and myocardial depression — monitor pulse and blood pressure and check for signs of worsening heart failure.</li></ul></li><li><strong>Clonidine </strong>— increased risk of withdrawal hypertension. Withdraw beta-blockers several days before slowly withdrawing clonidine.</li><li><strong>Corticosteroids, oestrogens</strong> — hypotensive effect antagonised with concomitant use.</li><li><strong>Digoxin</strong><ul><li>Concomitant administration of a beta-blocker and digoxin can reduce heart rate and prolong AV conduction time, increasing the risk of AV block and bradycardia. Monitor the pulse carefully; consider monitoring with electrocardiography (ECG).</li><li>An increase in plasma digoxin levels has been noted with carvedilol — monitor for signs of digoxin toxicity (confusion, anorexia, nausea, disturbance of colour vision) when starting, adjusting, or stopping carvedilol.</li></ul></li><li><strong>Dobutamine</strong> — increased risk of severe hypertension and bradycardia when non-cardioselective beta-blockers (nadolol, oxprenolol, pindolol, propranolol, timolol) are given with dobutamine.</li><li><strong>Fingolimod, mefloquine</strong> — increased risk of bradycardia </li><li><strong>Moxisylyte </strong>— increased risk of severe postural hypotension.</li><li><strong>Non-steroidal anti-inflammatory drugs</strong> — hypotensive effect antagonised with concomitant use.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/atrial-fibrillation/references/\">ABPI, 2019a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/atrial-fibrillation/references/\">ABPI, 2018a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/atrial-fibrillation/references/\">ABPI, 2019b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/atrial-fibrillation/references/\">ABPI, 2018b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/atrial-fibrillation/references/\">ABPI, 2017a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/atrial-fibrillation/references/\">ABPI, 2019c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/atrial-fibrillation/references/\">Joint Formulary Committee, 2019</a>]</p><!-- end field 619d8181-ab39-44ed-82ed-6a8e35797d42 --><!-- end item bd404169-ecd4-473b-b3fe-bb3b442dda29 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}